Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B13 | Q7Z5P4 | 11/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3056568 | 0.86 | ALDH1A1 (0.43) | HSD17B13 | |
| SCHEMBL6589975 | 0.81 | SMN1; SMN2 (0.53) | LMNARECQLMAPK10SMN1; SMN2HTT | |
| SCHEMBL21177886 | 0.81 | LMNA (0.35) | HSD17B13LMNANPSR1 | |
| SCHEMBL1012831 | 0.80 | ESR2 (0.52) | NPSR1NPC1 | |
| SCHEMBL3282947 | 0.80 | HDAC6 (0.38) | HSD17B13 | |
| SCHEMBL3178090 | 0.80 | PRKCA (0.42) | LMNAHTTNPSR1NPC1 | |
| SCHEMBL13646422 | 0.78 | TNF (0.56) | LMNASMN1; SMN2HTTNPSR1 | |
| SCHEMBL5565180 | 0.76 | TNF (0.43) | LMNARECQLMAPK10SMN1; SMN2HTT | |
| SCHEMBL5500566 | 0.76 | ESR1 (0.47) | LMNASMN1; SMN2HTTNPSR1 | |
| SCHEMBL27221551 | 0.74 | TNF (0.32) | HSD17B13NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928861-B1 | 4- (IH-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| US-7820683-B2 | 4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer | ASTRAZENECA AB (SE) | 2010-10-26 | — | — | US | disclosed |
| US-20100222344-A1 | 4-ANILINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB | 2010-09-02 | — | — | US | disclosed |
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2009-09-24 | — | — | US | disclosed |
| EP-1960371-B1 | QUINAZOLEINE DERIVATIVES USED AS INHIBITORS OF ERBB TYROSINE KINASE | ASTRAZENECA AB (SE) | 2009-09-16 | — | — | EP | disclosed |
| US-20090048251-A1 | 4-(1H-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2009-02-19 | — | — | US | disclosed |
| US-20090029968-A1 | QUINAZOLINE DERIVATIVES USED AS INHIBITORS OF ERBB TYROSINE KINASE | ASTRAZENECA AB (SE) | 2009-01-29 | — | — | US | disclosed |
| EP-1960371-A1 | QUINAZOLEINE DERIVATIVES USED AS INHIBITORS OF ERBB TYROSINE KINASE | AstraZeneca AB (SE) | 2008-08-27 | — | — | EP | disclosed |
| EP-1957499-A1 | 4-ANILINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | AstraZeneca AB (SE) | 2008-08-20 | — | — | EP | disclosed |
| EP-1940825-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | Astra Zeneca AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | BRADBURY ROBERT H | 2007-10-04 | — | — | US | disclosed |
| WO-2007063293-A1 | QUINAZOLEINE DERIVATIVES USED AS INHIBITORS OF ERBB TYROSINE KINASE | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007063291-A1 | 4-ANILINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2007-06-07 | — | — | WO | disclosed |
| WO-2007034143-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ASTRAZENECA AB (SE) | 2007-03-29 | — | — | WO | disclosed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118572-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239861-A1 | QUINAZOLINE DERIVATIVES AS ANTICANCER AGENTS | ABL1, ERBB2, CDK2 | HSD17B13 4111/4885LMNA 3904/4885TRPA1 3626/4885 |
| US-20090048251-A1 | 4-(1H-INDAZOL-5-YL-AMINO)-QUINAZOLINE COMPOUNDS AS ERBB RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | ERBB2, ERBB4, ERBB3 | HSD17B13 3930/4885LMNA 4418/4885TRPA1 3182/4885 |
| US-20090029968-A1 | QUINAZOLINE DERIVATIVES USED AS INHIBITORS OF ERBB TYROSINE KINASE | ERBB2, ABL1, ERBB3 | HSD17B13 3760/4885LMNA 4649/4885TRPA1 3568/4885 |
| US-20100222344-A1 | 4-ANILINO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | ERBB2, ABL1, ERBB4 | HSD17B13 3817/4885LMNA 4488/4885TRPA1 2769/4885 |
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | ERBB2, ERBB3, ERBB4 | HSD17B13 4560/4885LMNA 3173/4885TRPA1 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.